Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics (FHTX) provided a corporate update highlighting key achievements from 2021 and strategic priorities for 2022. The company reported a significant cash position of $454.3 million following a collaboration with Lilly, which included $380 million in upfront payments. Initial clinical data for its drug candidates, FHD-286 and FHD-609, is expected in the first half of 2022. Foghorn continues to advance its therapeutic pipeline targeting various cancers through its Gene Traffic Control® platform, enhancing its portfolio of oncology treatments.

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in Cowen’s 42nd Annual Health Care Conference, scheduled from March 7th to March 9th, 2022. The company will be featured in a panel addressing leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET. Foghorn is engaged in developing innovative medicines that target genetic dependencies in the chromatin regulatory system, having multiple oncology product candidates, with two in clinical studies. A webcast of the panel will be available for 90 days post-event on their website.

Foghorn Therapeutics (FHTX) announced the promotion of Steven Bellon, Ph.D., to Chief Scientific Officer, effective January 10, 2022. Bellon, a pivotal figure in Foghorn's drug discovery efforts, succeeds Carl Decicco, Ph.D., who is retiring. CEO Adrian Gottschalk praised Decicco's contributions, highlighting the advancement of two clinical programs in 2021. Bellon has been with Foghorn since 2016 and has played a critical role in developing the company's Gene Traffic Control® platform and advancing its diverse therapeutic pipeline, including over 15 programs in oncology.

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced its participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will present on January 10, with availability for 90 days. Foghorn focuses on developing novel therapies aimed at genetically determined dependencies within the chromatin regulatory system, particularly in oncology. Its Gene Traffic Control Platform supports the identification of potential drug targets, with multiple candidates currently being investigated in clinical studies.

Foghorn Therapeutics has entered into a strategic collaboration with Loxo Oncology at Lilly to develop novel oncology medicines utilizing Foghorn's Gene Traffic Control platform. The agreement includes a co-development and co-commercialization deal for Foghorn's selective BRM oncology program and another undisclosed program, alongside three additional discovery programs. Foghorn will receive $300 million upfront, along with an $80 million equity investment from Lilly at $20 per share. The partnership could yield up to $1.3 billion in potential milestones.

Loxo Oncology at Lilly and Foghorn Therapeutics announced a strategic collaboration aimed at developing novel oncology drugs using Foghorn's Gene Traffic Control platform. The agreement entails a $300 million upfront payment and an $80 million equity investment from Lilly. Foghorn will lead early research for their BRM-selective program, while Lilly will manage development and commercialization. They will share U.S. economics 50/50 and Foghorn stands to earn up to $1.3 billion in potential milestones. This collaboration addresses BRG1 mutations in various cancers, impacting a significant patient population.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company, will virtually participate in the 2021 Jefferies London Healthcare Conference. The event includes a presentation and investor 1x1 meetings, available on-demand from November 18, 2021, 8:00am GMT to November 19, 2021, 5:00pm GMT. Foghorn specializes in developing medicines that target the chromatin regulatory system and is advancing multiple oncology product candidates. For more details and the presentation access, visit www.foghorntx.com.

Foghorn Therapeutics (Nasdaq: FHTX) announced the dosing of the first patient in its phase 1 trial of FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. The company is also advancing FHD-286, an inhibitor for metastatic uveal melanoma and relapsed AML. Recent highlights include participation in the Targeted Protein Degradation Summit and a financial update showing cash reserves of $120.8 million as of September 30, 2021. Foghorn plans to release initial data from both clinical programs in late 2021 and early 2022.

Foghorn Therapeutics (Nasdaq: FHTX) announced that its VP of Chemistry, David Millan, PhD, will present at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Dr. Millan will discuss Foghorn's innovative protein degrader platform and its clinical asset, FHD-609, a heterobifunctional degrader of BRD9 aimed at treating synovial sarcoma. The company is advancing over eight protein degrader programs, with FHD-609 recently entering clinical trials, demonstrating potential in transforming treatment options for various cancers.